Delving into the Latest Updates on MLN2468 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication-

Inactive Indication

Gastrooesophageal junction cancerstomach adenocarcinoma

Originator Organization-

Active Organization-

Inactive Organization

Bristol Myers Squibb Co.

License Organization-

Drug Highest PhaseSuspendedPhase 3

First Approval Date-

Regulation-

Login to view timeline

评价和对比 ONO-4538 联用替加氟–吉美拉西–奥替拉西钾（S-1 治疗）或卡培他滨 + 奥沙利铂（CapeOX 治疗）术后辅助性化疗与安慰剂联用 S-1 治疗或 CapeOX 治疗（下文简称化疗）在 D2 或更大范围的淋巴结清扫术后的 pStage III 期胃癌（包括食管胃结合部癌）治疗中的疗效和安全性

[Translation]

To evaluate and compare the efficacy and safety of ONO-4538 combined with tegafur-gimeracil-oteracil potassium (S-1 treatment) or capecitabine + oxaliplatin (CapeOX treatment) as postoperative adjuvant chemotherapy with placebo combined with S-1 treatment or CapeOX treatment (hereinafter referred to as chemotherapy) in the treatment of pStage III gastric cancer (including esophagogastric junction cancer) after D2 or greater lymph node dissection

Start Date14 Jun 2018

Sponsor / Collaborator

Bristol-Myers Squibb (China) Investment Co. Ltd.

[+2]

100 Clinical Results associated with MLN2468

Login to view more data

100 Translational Medicine associated with MLN2468

Login to view more data

100 Patents (Medical) associated with MLN2468

Login to view more data

100 Deals associated with MLN2468

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastrooesophageal junction cancer	Phase 3	Japan	Bristol Myers Squibb Co.	31 Jan 2017
Gastrooesophageal junction cancer	Phase 3	South Korea	Bristol Myers Squibb Co.	31 Jan 2017
stomach adenocarcinoma	Phase 3	Japan	Bristol Myers Squibb Co.	31 Jan 2017
stomach adenocarcinoma	Phase 3	South Korea	Bristol Myers Squibb Co.	31 Jan 2017